Skip to main
DNTH

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc. has a promising outlook due to the anticipated 25%-30% increase in shares, supported by a 70% probability of achieving a base case scenario with a projected 15% rise. The company's pipeline features Claseprubart, which exhibits greater potency than its predecessor, riliprubart, suggesting a favorable efficacy profile that could enhance its market potential as the company advances to Part B of its clinical assessments. Additionally, the updated cash position of approximately $514 million at year-end 2025, along with revisions to the valuation model that raise the target from $46 to $55, further solidifies a positive financial outlook for Dianthus Therapeutics.

Bears say

Dianthus Therapeutics Inc. may face significant financial challenges due to its inability to secure adequate funds, which could hinder the advancement of its clinical pipeline. The reliance on successful fundraising raises concerns about liquidity and operational sustainability, especially as the company is still in the clinical stage. Additionally, potential setbacks in their interim results could further complicate their financial outlook and impede progress on developing their therapies.

DNTH has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 10 analysts, DNTH has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.